Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12672
Title: Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
Austin Authors: Price, Timothy J;Bruhn, M A;Lee, C K;Hardingham, J E;Townsend, A R;Mann, K P;Simes, J;Weickhardt, A ;Wrin, J W;Wilson, K;Gebski, V;Van Hazel, G;Robinson, B;Cunningham, D;Tebbutt, Niall C 
Affiliation: School of Medical Sciences, University of Adelaide, Adelaide, SA 5005, Australia
Royal Marsden Hospital, London, UK
Sir Charles Gardiner Hospital, Perth, WA, Australia
Haematology-Oncology Department, The Queen Elizabeth Hospital, Woodville, SA 5011, Australia
NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW 2050, Australia
Austin Health, Heidelberg, VIC 3084, Australia
Haematology-Oncology Department, The Queen Elizabeth Hospital, Woodville, SA 5011, Australia
Ludwig Institute for Cancer Research, Heidelberg, VIC 3084, Australia
School of Medical Sciences, University of Adelaide, Adelaide, SA 5005, Australia
School of Medicine, University of Adelaide, Adelaide, SA 5005, Australia
Christchurch Hospital, Christchurch, New Zealand.
Issue Date: 17-Mar-2015
Publication information: British Journal of Cancer 2015; 112(6): 963-70
Abstract: Mutations affecting RAS genes are now established predictive markers of nonresponse to anti-EGFR antibodies in advanced CRC. This analysis assessed the prognostic and predictive impact of extended RAS and PIK3CA gene mutation status in patients receiving capecitabine plus or minus bevacizumab (±mitomycin C) in the randomised phase III MAX study.DNA was extracted from archival macrodissected formalin-fixed paraffin-embedded tumour tissue. Mutation status was determined using pyrosequencing, confirmed with Sanger sequencing (for equivocal RAS) and correlated with efficacy outcomes. Predictive analyses were undertaken using a test for interaction involving both C vs CB+CBM.Of the available 280 of the 471 (59.4%) patients, mutations in KRAS exons 2, 3 and 4 and NRAS 2, 3 and 4 were as follows: 32%, 2.9%, 2.2%, 1.4%, 0.7% and 0% (total RAS MT 39%). The PIK3CA MT rate was 7.5% exon 9 and 3.6% exon 20. Extended RAS gene mutation status (WT vs MT) had no prognostic impact for PFS (HR 0.91 (0.71-1.17)) or OS (HR 0.95 (0.71-1.25)). The RAS gene mutation status was not predictive of the effectiveness of bevacizumab for PFS (HR 0.56 (0.37-0.85) for RAS MT and HR 0.69 (0.5-0.97) for RAS WT; P for interaction 0.50). The PIK3CA mutation was neither predictive for bevacizumab effect nor prognostic.Of KRAS exon 2 WT patients, 10% had additional RAS mutations. Neither all RAS gene mutation status nor PIK3CA mutation status was prognostic for PFS or OS, or predictive of bevacizumab outcome in patients with advanced CRC.
Gov't Doc #: 25742472
URI: https://ahro.austin.org.au/austinjspui/handle/1/12672
DOI: 10.1038/bjc.2015.37
Journal: British Journal of Cancer
URL: https://pubmed.ncbi.nlm.nih.gov/25742472
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

10
checked on Mar 18, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.